Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03902184 · ClinicalTrials.gov registry record · Phase 2
IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
A Phase 2 study of Lymphoma, T-Cell and Lymphoma, T-Cell, Cutaneous, sponsored by Innate Pharma.
- Active
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
- 20
- Study locations
NCT03902184: Active Phase 2 study of Lymphoma, T-Cell and Lymphoma, T-Cell, Cutaneous, sponsored by Innate Pharma.
NCT03902184 is a Phase 2 study of Lymphoma, T-Cell and Lymphoma, T-Cell, Cutaneous that is active but no longer recruiting, run by Innate Pharma. The registered enrollment target is 170 participants, above the 107-participant average among 9 other Lymphoma, T-Cell trials with a reported enrollment target (59% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03902184, a Phase 2 study of Lymphoma, T-Cell and Lymphoma, T-Cell, Cutaneous, is active but no longer recruiting, sponsored by Innate Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.
Primary Outcome
Using the Olsen (2011, JCO) criteria (All cohorts)
Conditions Studied
Interventions
- BIOLOGICAL IPH4102
Study Locations (20)
California
- University of California, Los Angeles (UCLA) - Medical Center - Los Angeles
- Irvine Medical Center - Orange
- Stanford University - Stanford
Pennsylvania
- University of Pennsylvania - Philadelphia
- Thomas Jefferson University - Philadelphia
- University of Pittsburgh School of Medicine - Pittsburgh
Other
- Universitätsklinik für Dermatologie Medizinische Universität Graz - Graz
- Medizinische Universitaet Wien - Vienna
- Institut Jules Bordet - Brussels
Florida
- Moffitt Cancer Center - Tampa
- University of South Florida - Tampa
New York
- Universal Dermatology, PLLC68 - Fairport
- Columbia University Department of Dermatology - New York
Alabama
- University of Alabama at Birmingham - Birmingham
Illinois
- Northwestern University The Feinberg School of Medicine - Chicago
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2019-05-22 |
| Est. Completion | 2026-01-31 |
| Phase | Phase 2 |
What the registry record for NCT03902184 still lists
NCT03902184 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, above the 107-participant average among 9 other Lymphoma, T-Cell trials with a reported enrollment target (59% higher).
The record links to 3 conditions, with Lymphoma, T-Cell appearing as the primary indexed condition, and to 1 intervention - of which IPH4102 is the first listed.
NCT03902184 names 20 study sites across 12 states, led by California, Pennsylvania, Other.
Frequently Asked Questions
What is clinical trial NCT03902184 about?
NCT03902184 is a clinical study titled "IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma". This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.
What is the current status of trial NCT03902184?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2019-05-22. Estimated completion is 2026-01-31.
What conditions does trial NCT03902184 study?
This clinical trial studies the following conditions: Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome.
What interventions are being tested in trial NCT03902184?
The interventions under investigation include: IPH4102 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03902184?
This trial is sponsored by Innate Pharma, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03902184 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, T-Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03902184's enrollment target sits among peer trials
170 3rd of 9 higher than 7 of 9 other Lymphoma, T-Cell trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma, T-Cell trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MB-105 in Patients With CD5 Positive T-cell Lymphoma
RECRUITING · Phase 2
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
-
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
COMPLETED · Phase 2
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
RECRUITING · Phase 1
-
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI